Why plasma‐derived factor VIII?

Abstract

1. Hoyer LW, Hemophilia A. N Engl J Med. 1994;330(1):38-47. 2. Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91(3):931-972. 3. Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2‐year national surveillance study by the United Kingdom Haemophilia Centre Doctors Organisation. Blood. 2007;109(5):1870-1877. 4. Godje O, Haushofer M, Lamm P, Reichart B. The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg. 1998;46(5):263‐267. 5. Biswas A, Ivaskevicius V, Thomas A, Oldenburg J. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie. 2014;34(2): 160‐166. 6. Tarantino MD, Cuker A, Hardesty B, Roberts JC, Sholzberg M. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. Haemophilia. 2017;23(1):25-32. 7. Peerschke EI, Castellone DD, Ledford‐Kraemer M, Van Cott EM, Meijer P, Committee N. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol. 2009;131(4): 552-558. 8. CorifactTM 250 / CorifactTM 1250 Factor XIII Concentrate, Human [Product Monograph]. CSL Behring Canada, Inc., Ottawa, ON; December 2015. http://labeling.cslbehring.ca/PM/CA/Corifact/ EN/Corifact‐Product‐Monograph.pdf. Accessed April 15, 2018. 9. Carmassi F, Giannarelli C, De Giorgi A, De Negri F. Combined factor VIII and IX inhibitors in a non‐haemophilic patient: successful treatment with immunosuppressive drugs. Haemophilia. 2007;13(1):106‐107. 10. Lorenz R, Born P, Classen M. Substitution of factor XIII concentrate in treatment refractory ulcerative colitis. A prospective pilot study. Med Klin (Munich). 1994;89(10):534-537.